Roth Capital Partners

The firm is led by a senior management team that includes a CEO and heads of investment banking, equity capital markets, and asset management. Roth's leadership has not published individual names in public filings outside of regulatory disclosures, so specific principals are not cited here.

Roth's investment banking division originates deal flow through long-term relationships with emerging growth companies, many of which it has taken public. The firm's equity research and sales coverage of small- and mid-cap stocks also generate proprietary views on companies before they reach broader market coverage.

Roth Capital Partners operates as a full-service investment bank and SEC-registered investment adviser. It is not a family office. The firm underwrites public offerings, advises on mergers and acquisitions, and manages client capital through separately managed accounts and funds.

Roth focuses on growth-stage companies, typically in the public and near-public markets. It leads IPOs and follow-on offerings for small- to mid-cap companies and also participates in private placements and PIPEs. The firm's venture capital arm invests in earlier-stage companies, but its core market is post-revenue growth.

Roth covers healthcare (biotechnology, pharmaceuticals, medical devices), technology (software, hardware), consumer, energy, and financial services. Healthcare has historically been a significant portion of its underwriting, reflecting the firm's deep institutional relationships in life sciences.

Yes, the Roth DOEN Foundation is the firm's charitable arm. It supports initiatives in community development, education, and environmental sustainability. Roth does not disclose the foundation's asset size.

Roth's asset management division may co-invest alongside institutional clients in certain transactions, particularly in PIPE and follow-on financings. The firm's public-profile underwriting does not highlight a separate co-investment program for external limited partners.